Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2020

01-12-2020 | Hepatitis B | Hepatitis B (JK Lim, Section Editor)

Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV

Authors: Sasan Sakiani, Bilal Asif, Alexander Yang, Christopher Koh

Published in: Current Hepatology Reports | Issue 4/2020

Login to get access

Abstract

Purpose of Review

Hepatitis B virus (HBV) infection is one of the most common viral infections worldwide with an estimated 2 billion people exposed to HBV and 240 million with active chronic infection. Despite this, less than 1% of patients with chronic HBV infection receive treatment, and less than 3% of those achieve functional cure with traditional therapies. This review summarizes recent advances in the treatment of chronic HBV utilizing nucleic acid polymers (NAP) and entry inhibitors (EI).

Recent Findings

A recent phase 2 study evaluating the use of NAP following tenofovir and pegylated interferon (PEG-IFN) demonstrated increased rates of functional cure which persisted in 35% of patients after 48 weeks of follow-up. In addition, the EI Myrcludex B has demonstrated HBsAg response in up to 40% of patients when used in combination with PEG-IFN at week 72.

Summary

Functional cure is considered the “holy grail” of treatment, and many new therapies are under investigation for the treatment of chronic HBV. As we work towards functional cure for chronic HBV, NAPs and EIs have shown efficacy in reducing HBV DNA and HBsAg levels and have emerged as potential therapeutic agents that may lead to a functional cure for HBV.
Literature
1.
2.
Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2011;9(1):64–70.PubMed
3.
Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350(11):1118–29.PubMed
4.
Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014;16:365.PubMed
5.
Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. 2019;156(2):461–476.e1.PubMed
6.
World Health Organization (WHO). Hepatitis B: key facts. WHO. 2019.
7.
Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.PubMed
8.
Lok ASF. Prevention of hepatitis B virus-related hepatocellular carcinoma. In: Gastroenterology. 2004
9.
Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol. 2014;20(2):401–13.PubMedPubMedCentral
10.
Dianzani F, Antonelli G, Capobianchi MR. The biological basis for clinical use of interferon. J Hepatol. 1990;11:S5–S10.PubMed
11.
Wong VWS, Wong GLH, Yan KKL, Chim AML, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;52:S399.
12.
Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clinics Liver Disease. 2016;20:645–65.
13.
Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis b. J Antimicrob Chemother. 2011;66(12):2715-2725
14.
Gish RG, Chang TT, Lai CL, De Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):16–22.PubMed
15.
Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-Term Safety of Lamivudine Treatment in Patients with Chronic Hepatitis B. Gastroenterology. 2003;125(6):1714–22.PubMed
16.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–51.PubMed
17.
Marcellin P, Heathcote EJ, Buti M, Gane E, De Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–55.PubMed
18.
Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672–81.PubMed
19.
Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005;12(4):333–45.PubMed
20.
Prescott NA, Bram Y, Schwartz RE, David Y. Targeting hepatitis B virus covalently closed circular DNA and hepatitis B virus X protein: recent advances and new approaches. ACS Infect Dis. 2019;5:1657–67.PubMedPubMedCentral
21.
Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA – The holy grail to hepatitis B cure. J Hepatol. 2016;64(1 Supplement):S41–8.PubMed
22.
Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: a wave of new therapies on the horizon. Antivir Res. 2015;121:69–81.PubMed
23.
Eckstein F Phosphorothioates, essential components of therapeutic oligonucleotides. Vol. 24, Nucleic Acid Therapeutics. Mary Ann Liebert Inc.; 2014. p. 374–87.
24.
Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob Agents Chemother. 2013;57(11):5291–8.PubMedPubMedCentral
25.
Guzman EM, Cheshenko N, Shende V, Keller MJ, Goyette N, Juteau J-M, et al. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antivir Ther. 2007;12(8):1147–56.PubMed
26.
Matsumura T, Hu Z, Kato T, Dreux M, Zhang Y-Y, Imamura M, et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. YGAST. 2009;137:673–81.
27.
Vaillant A, Juteau J-M, Lu H, Liu S, Lackman-Smith C, Ptak R, et al. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 Core formation downloaded from. Antimicrob Agents Chemother. 2006;50(4):1393–401.PubMedPubMedCentral
28.
Kocisko DA, Vaillant A, Lee KS, Arnold KM, Bertholet N, Race RE, et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother. 2006;50(3):1034–44.PubMedPubMedCentral
29.
Schultz U, Grgacic E, Nassal M. Duck hepatitis B virus: an invaluable model system for HBV infection. Adv Virus Res. 2004;63:1–70.PubMed
30.
Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, et al. Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes. PLoS One. 2017;12(6):1–15.
31.
Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 2011;39(11):4795–807.PubMedPubMedCentral
32.
Yang B, Ming X, Cao C, Laing B, Yuan A, Porter MA, et al. High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res. 2015;43(4):1987–96.PubMedPubMedCentral
33.
•• Blanchet M, Sinnathamby V, Vaillant A, Labonté P. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells. Antivir Res. 2019;164:97–105 First proposed NAP mechanism of action during SVP assembly.PubMed
34.
Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 2013;57(11):5299–306.PubMedPubMedCentral
35.
Krieg AM. Immune effects and mechanisms of action of CpG motifs. Vol. 19, Vaccine. Elsevier BV; 2000. p. 618–22.
36.
Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS One. 2015;10(11):e0140909.PubMedPubMedCentral
37.
Roehl I, Seiffert S, Brikh C, Quinet J, Jamard C, Dorfler N, et al. Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy. Mol Ther - Nucleic Acids. 2017;8:1–12.PubMedPubMedCentral
38.
• Al-Mahtab M, Bazinet M, Vaillant A. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg + chronic hepatitis B infection. PLoS One. 2016;11(6):e0156667 First NAP clinical trial showing successful antiviral activity in humans.PubMedPubMedCentral
39.
•• Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180–94 Largest clinical trial to date investigating NAP in combination therapy with traditional HBV therapies.PubMed
40.
Shekhtman L, Borochov N, Cotler S, Hershkovich L, Uprichard S, Al-Mahtab M, et al. Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection. J Hepatol. 2018;68:S508.
41.
42.
Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis b virus variant defective in pre-s2 protein expression in a chronic carrier. Virology. 1993;194:137–48.PubMed
43.
•• Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049 Key study that identified NTCP as the receptor for HBV, opening the possibility of a new therapeutic target.PubMedPubMedCentral
44.
Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146(4):1070–83.PubMed
45.
Yan H, Liu Y, Sui J, Li W. NTCP opens the door for hepatitis B virus infection. Antivir Res. 2015;121:24–30.PubMed
46.
Huang H-C, Chen C-C, Chang W-C, Tao M-H, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012;86:9443–53.PubMedPubMedCentral
47.
Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018;7(1):186.PubMedPubMedCentral
48.
• König A, Döring B, Mohr C, Geipel A, Geyer J, Glebe D. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J Hepatol. 2014;61(4):867–75 Study demonstrating that NTCP can be used as a target for entry inhibitors.PubMed
49.
Fu LL, Liu J, Chen Y, Wang FT, Wen X, Liu HQ, et al. In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy. Cell Prolif. 2014;47:326–35.PubMed
50.
Serrao E, Xu ZL, Debnath B, Christ F, Debyser Z, Long YQ, et al. Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction. Bioorg Med Chem. 2013;21:5963–72.PubMed
51.
Saso W, Tsukuda S, Ohashi H, Fukano K, Morishita R, Matsunaga S, et al. A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction. Biochem Biophys Res Commun. 2018;501(2):374–9.PubMed
52.
Osada H. Introduction of new tools for chemical biology research on microbial metabolites. Bioscience, Biotechnology and Biochemistry. 2010;74(6):1135-1140
53.
Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, et al. Chemical array system, a platform to identify novel hepatitis b virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide. Sci Rep. 2018;8:2769.PubMedPubMedCentral
54.
Passioura T, Suga H. A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets. Chem Commun. 2017;53(12):1931–40.
55.
Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, et al. De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. Cell Chem Biol. 2018;25(7):906–915.e5.PubMed
56.
Miyakawa K, Matsunaga S, Yamaoka Y, Dairaku M, Fukano K, Kimura H, et al. Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide. Oncotarget. 2018;9(34):23681–94.PubMedPubMedCentral
57.
Goh B, Choi J, Kang JA, Park SG, Seo J, Kim TY. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors. J Pharm Biomed Anal. 2020;178:112959.PubMed
58.
Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol. 2017;66:685–92.PubMed
59.
Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, et al. Cyclosporin a and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014;59:1726–37.PubMedPubMedCentral
60.
Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, et al. Cyclosporin a inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014;60:723–31.PubMed
61.
Donkers JM, Zehnder B, Van Westen GJP, Kwakkenbos MJ, Ijzerman AP, Oude Elferink RPJ, et al. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Sci Rep. 2017;7(1):15307.PubMedPubMedCentral
62.
Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun. 2014;443:808–13.PubMed
63.
Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antivir Res. 2013;97(2):195–7.PubMed
64.
Abbas Z, Saad M, Asim M, Abbas M, Samejo SA. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D. Turk J Gastroenterol. 2020;31:136–41.PubMedPubMedCentral
65.
Fukano K, Tsukuda S, Oshima M, Suzuki R, Aizaki H, Ohki M, et al. Troglitazone impedes the oligomerization of sodium taurocholate cotransporting polypeptide and entry of hepatitis B virus into hepatocytes. Front Microbiol. 2019;9:3257.PubMedPubMedCentral
66.
Nio Y, Akahori Y, Okamura H, Watashi K, Wakita T, Hijikata M. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide. Biochem Biophys Res Commun. 2018;501:820–5.PubMed
67.
Blanchet M, Sureau C, Labonté P. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. Antivir Res. 2014;106:111–5.PubMed
68.
Ko C, Park WJ, Park S, Kim S, Windisch MP, Ryu WS. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. Antivir Ther. 2015;20:835–42.PubMed
69.
Jun WX, Hu W, Yu ZT, Ying MY, Nan LN, Qi WS. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+−dependent taurocholate cotransporting polypeptide activity. Antivir Res. 2015;120:140–6.
70.
Pereira IVA, Buchmann B, Sandmann L, Sprinzl K, Schlaphoff V, Döhner K, et al. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP). PLoS One. 2015;10(2):e0117152.
71.
Umetsu T, Inoue J, Kogure T, Kakazu E, Ninomiya M, Iwata T, et al. Inhibitory effect of silibinin on hepatitis B virus entry. Biochem Biophys Reports. 2018;14:20–5.
72.
Bruss V, Hagelstein J, Gerhardt E, Galle PR. Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology. 1996;218(2):396–9.PubMed
73.
Gripon P, Seyec JLE, Rumin S, Guguen-Guillouzo C. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology. 1995;213:292–9.PubMed
74.
•• Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol. 2005;79(3):1613–22 Important study that led to Myrcludex B.PubMedPubMedCentral
75.
Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol. 2010;84:1989–2000.PubMed
76.
Glebe D, Urban S, Knoop EV, Çaǧ N, Krass P, Grün S, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology. 2005;129:234–45.PubMed
77.
Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, Von Weizsäcker F, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008;26(3):335–41.PubMed
78.
Volz T, Allweiss L, ḾBarek MB, Warlich M, Lohse AW, Pollok JM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58(5):861–7.PubMed
79.
Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685–94.PubMed
80.
Schieck A, Schulze A, Gähler C, Müller T, Haberkorn U, Alexandrov A, et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology. 2013;58(1):43–53.PubMed
81.
Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483–9.PubMed
82.
83.
Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65:490–8.PubMed
84.
• Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018;68(1):S3 Phase II study demonstrating HBsAg decline and negativation.
85.
Wedemeyer H A Multicenter, open-label, randomized clinical study to assess efficacy and safety of 3 doses of Myrcludex B for 24 weeks in combination with tenofovir compared to tenofovir alone to suppress HBV replication in patients with chronic hepatitis D [Internet]. Available from: https://​clinicaltrials.​gov/​ct2/​show/​study/​NCT03546621. Accessed 28 Sept 2020.
86.
Wedemeyer H, Schöneweis K, Bogomolov PO, Voronkova N, Chulanov V, Stepanova T, et al. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. J Hepatol. 2019;70(1):e81 Available from: https://​linkinghub.​elsevier.​com/​retrieve/​pii/​S061882781930141​0. Accessed 28 Sept 2020.
87.
Metadata
Title
Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV
Authors
Sasan Sakiani
Bilal Asif
Alexander Yang
Christopher Koh
Publication date
01-12-2020
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2020
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-020-00550-w

Other articles of this Issue 4/2020

Current Hepatology Reports 4/2020 Go to the issue

Fatty Liver Disease (D Halegoua-DeMarzio, Section Editor)

Current and Emerging Treatments for Non-alcoholic Steatohepatitis

Hepatic Cancer (N Parikh, Section Editor)

Current Transplant Criteria for Hepatocellular Carcinoma—Overuse or Underuse

Hepatic Cancer (N Parikh, Section Editor)

Genomic Landscape of HCC

Hepatitis B (JK Lim, Section Editor)

The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B

Hepatic Cancer (N Parikh, Section Editor)

LI-RADS Imaging Criteria for HCC Diagnosis and Treatment: Emerging Evidence

Fatty Liver Disease (D Halegoua-DeMarzio, Section Editor)

Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits